Trial · NCT02115113
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) | Group A (Tacrolimus Elimination Arm) | 85.50 | Standard Error 3.97 | mL/min/1.73m^2 | |
| Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) | Group B (Tacrolimus Minimization Arm) | 80.26 | Standard Error 3.87 | mL/min/1.73m^2 | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | tBPAR, 12 months | 2 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | tBPAR, 12 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | AR, 12 months | 2 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | AR, 12 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | GL, 12 months | 0 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | GL, 12 months | 0 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | Death, 12 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | Death, 12 months | 0 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | tBPAR, 18 months | 2 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | tBPAR, 18 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | AR, 18 months | 2 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | AR, 18 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | GL, 18 months | 0 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | GL, 18 months | 0 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group A (Tacrolimus Elimination Arm) | Death, 18 months | 1 | Participants | |
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D) | Group B (Tacrolimus Minimization Arm) | Death, 18 months | 1 | Participants | |
| Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant | Group A (Tacrolimus Elimination Arm) | -0.11 | Standard Error 0.04 | mg/dL | |
| Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant | Group B (Tacrolimus Minimization Arm) | -0.05 | Standard Error 0.03 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02115113/results